---
figid: PMC9664612__12885_2022_10221_Fig1_HTML
pmcid: PMC9664612
image_filename: 12885_2022_10221_Fig1_HTML.jpg
figure_link: /pmc/articles/PMC9664612/figure/Fig1/
number: Fig. 1
figure_title: ''
caption: 'VICTOR trial schema VICTOR trial schema showing the patient pathway highlighting
  treatment decisions depending on disease status. #, cycles; CR, complete remission/response;
  DA, daunorubicin; DAGO, daunorubicin, cytarabine and gemtuzumab ozogamicin; FLAG-IDA,
  fludarabine, cytarabine and idarubicin; HIDAC, high-dose cytarabine; LDAC, low-dose
  cytarabine; MRD, minimal residual disease; R, randomisation; VEN, venetoclax'
article_title: 'Venetoclax combined with low dose cytarabine compared to standard
  of care intensive chemotherapy for the treatment of favourable risk adult acute
  myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre,
  molecularly-guided randomised, phase II trial.'
citation: Richard Dillon, et al. BMC Cancer. 2022;22:1174.
year: '2022'

doi: 10.1186/s12885-022-10221-2
journal_title: BMC Cancer
journal_nlm_ta: BMC Cancer
publisher_name: BioMed Central

keywords:
- Clinical trial
- Acute myeloid leukaemia
- Bayesian non-inferiority design
- Adaptive design
- Venetoclax
- Low-dose cytarabine

---
